The FDA is not our problem (nor MMs or any other boogeyman). The issue is whether we can attract a pharma partner with our OM and IBD trial results. There's interest, but no one has decided (yet) to pull the trigger and license from us for those indications. I am hopeful and optimistic - like the company - that one will. The results also aren't strong enough to generate confidence from public investors, and private investors aren't in the business of buying high and selling low. This is why it's an imperative that we get a partner, which is what management is focused on. In the meantime they have been doing what they can on a limited budget to keep making preparations for advanced trials, including in Europe where the EMA is perhaps more enthusiastic.
News 
Market Data 
Discover 
AI
